

# BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD LEVEL HOSPITAL

Poster number:  
**1ISG-002**

Authors: N. BÁEZ, C. ROMERO LARA, MD. SANTOS RUBIO, M. MUÑOZ BURGOS, H. RODRÍGUEZ RAMALLO.  
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO, HOSPITAL PHARMACY, SEVILLE, SPAIN.

## Background


Although parenteral nutrition (PN) is a lifesaving therapy in undernourished patients, its use may be associated with metabolic complications

## Purpose

To evaluate the budgetary impact of the repackaging of the commercial dose of 150 mg in doses of 75 mg.

## Materials

A pharmacoeconomic study was carried out in which the savings obtained by repacking the dose of 150 mg in doses of 75 mg → both commercial presentations have the same price.



The cost was calculated, taking into account the number of doses and the duration of treatment in each patient.

## Results:

- **73 patients** were treated with alirocumab during the period of study.
- **A saving of € 1077.93 per patient** was obtained with the repackaging of the 150 mg dose into 75 mg.

Presentation	Praluent <sup>®</sup> 150 mg	Praluent <sup>®</sup> 75 mg	Repackaged 75 mg Alirocumab
Price	€ 192,4	€ 192,4	€ 96,2

Presentation	Praluent <sup>®</sup> 75 mg	Repackaged 75 mg Alirocumab
Total treatment cost	€ 248,270	€ 167,425

## Conclusions

The budgetary impact of the repackaging of the commercial presentation of 150 mg in doses of 75 mg is a cost-effective practise, simple and easy to implement in hospitals.

